Northern Trust Corp increased its holdings in Relx Plc (NYSE:RELX - Free Report) by 51.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,191,588 shares of the technology company's stock after acquiring an additional 745,532 shares during the quarter. Northern Trust Corp owned approximately 0.12% of Relx worth $99,542,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Dimensional Fund Advisors LP grew its position in Relx by 4.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,189,886 shares of the technology company's stock valued at $144,885,000 after buying an additional 121,831 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Relx by 50.3% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,968,739 shares of the technology company's stock valued at $89,420,000 after acquiring an additional 658,655 shares in the last quarter. Envestnet Asset Management Inc. increased its stake in shares of Relx by 2.6% during the fourth quarter. Envestnet Asset Management Inc. now owns 1,898,927 shares of the technology company's stock worth $86,249,000 after acquiring an additional 48,336 shares during the period. Natixis Advisors LLC raised its holdings in Relx by 2.8% during the fourth quarter. Natixis Advisors LLC now owns 1,202,592 shares of the technology company's stock worth $54,622,000 after purchasing an additional 32,739 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Relx in the fourth quarter valued at about $44,516,000. Hedge funds and other institutional investors own 15.02% of the company's stock.
Relx Price Performance
RELX stock traded up $0.11 during midday trading on Friday, hitting $53.61. 235,972 shares of the stock were exchanged, compared to its average volume of 706,536. The stock's 50-day moving average price is $50.49 and its 200-day moving average price is $48.65. The company has a debt-to-equity ratio of 1.46, a quick ratio of 0.47 and a current ratio of 0.52. The stock has a market cap of $99.22 billion, a price-to-earnings ratio of 28.82, a PEG ratio of 2.73 and a beta of 0.86. Relx Plc has a fifty-two week low of $42.77 and a fifty-two week high of $55.21.
Relx Increases Dividend
The firm also recently disclosed a semi-annual dividend, which will be paid on Wednesday, June 25th. Investors of record on Friday, May 9th will be given a $0.5586 dividend. The ex-dividend date of this dividend is Friday, May 9th. This is a positive change from Relx's previous semi-annual dividend of $0.23. This represents a dividend yield of 1.6%. Relx's payout ratio is currently 59.68%.
Analyst Upgrades and Downgrades
RELX has been the subject of several recent analyst reports. Barclays raised Relx from an "equal weight" rating to an "overweight" rating in a report on Friday, March 14th. StockNews.com lowered shares of Relx from a "buy" rating to a "hold" rating in a research report on Tuesday, March 4th. Morgan Stanley reaffirmed an "overweight" rating on shares of Relx in a research note on Wednesday, April 16th. Finally, The Goldman Sachs Group initiated coverage on shares of Relx in a research note on Wednesday, March 26th. They issued a "buy" rating for the company. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Buy".
Check Out Our Latest Research Report on Relx
Relx Company Profile
(
Free Report)
RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.
Further Reading
Before you consider Relx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Relx wasn't on the list.
While Relx currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
